{"id":"W4281682739","doi":"10.1200/jco.2022.40.16_suppl.5505","title":"Pembrolizumab, maveropepimut-S, and low-dose cyclophosphamide in advanced epithelial ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Ovarian cancer; Regimen; Internal medicine; Cyclophosphamide; Gastroenterology; Oncology; Urology; Cancer; Chemotherapy; Surgery; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001508125,0.0006635705,0.0007919801,0.0002858935,0.0002493675,0.0006500726,0.000557832,0.0006503685,0.003193547],"category_scores_gemma":[0.0008342293,0.0002580158,0.0007265928,0.0003066887,0.0004192439,0.0007351079,0.0003190846,0.001420529,0.0004984696],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008942258,"about_ca_system_score_gemma":0.001036298,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001037017,"about_ca_topic_score_gemma":0.003477713,"domain_scores_codex":[0.9997012,0.0001458789,0.00001507345,0.00004636104,0.00003251803,0.00005899496],"domain_scores_gemma":[0.9994647,0.0000890123,0.0001333804,0.00004675915,0.00003245795,0.0002338326],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7242321,0.02689764,0.02363007,0.001066928,0.002085503,0.0002248086,0.0002800941,0.003893934,0.02477763,0.0005315592,0.01212824,0.1802515],"study_design_scores_gemma":[0.6372809,0.2796718,0.06263954,0.0001249092,0.001493613,0.0006500139,0.000121464,0.002518158,0.00374563,0.0007056448,0.01101002,0.00003834912],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909109,0.002644683,0.0002849611,0.0005134376,0.00006297242,0.001421814,0.001779288,0.00006161113,0.002320374],"genre_scores_gemma":[0.9870147,0.002068089,0.0009547747,0.0007194779,0.00009451476,0.001939223,0.004725896,0.00002633433,0.002457001],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003193547,"threshold_uncertainty_score":0.01068354,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03948700336653758,"score_gpt":0.3886118903320324,"score_spread":0.3491248869654948,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}